CYBN
CybinCYBN
CYBN
About: Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
Employees: 50
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
6.99% less ownership
Funds ownership: 43.33% [Q2] → 36.34% (-6.99%) [Q3]
28% less capital invested
Capital invested by funds: $89.2M [Q2] → $64.6M (-$24.6M) [Q3]
54% less funds holding
Funds holding: 98 [Q2] → 45 (-53) [Q3]
93% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 57
98% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 40
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$86
795%
upside
Avg. target
$138
1,336%
upside
High target
$190
1,877%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity Sumant Kulkarni 22% 1-year accuracy 7 / 32 met price target | 795%upside $86 | Buy Maintained | 19 Nov 2024 |
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target | 1,877%upside $190 | Buy Reiterated | 19 Nov 2024 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the presentation of two posters at the American College of Neuropsychopharmacology (“ACNP”) Annual Meeting taking place December 8-11, 2024, in Phoenix, Arizona. The data presented include 12-month efficacy result.
Neutral
Business Wire
2 weeks ago
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, and Amir Inamdar, MBBS, DNB (Psych), FFPM, Cybin's Chief Medical Officer, will participate in the Water Tower Research Fireside Chat Series taking place.
Neutral
Business Wire
1 month ago
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced unprecedented 12-month efficacy data from its Phase 2 study of CYB003, a proprietary deuterated psilocin program in development for the potential adjunctive treatment of major depressive disorder (“MDD”). As previ.
Neutral
Business Wire
1 month ago
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer,.
Neutral
Business Wire
1 month ago
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of PARADIGMTM, its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the.
Positive
Proactive Investors
1 month ago
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noting that psychedelics have reportedly helped his family and friends recover from trauma, severe depression and obsessive-compulsive disorder.
Neutral
Business Wire
1 month ago
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will be speaking at the 2024 Milken Institute Future of Health Summit on a panel entitled “The Next Frontier in Mental Health Research.” “We share the.
Neutral
Business Wire
1 month ago
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the Company's CYB005 phene.
Positive
Seeking Alpha
2 months ago
Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +
The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 11th - 17th, aiming to inspire discussion and provide investment ideas. AST SpaceMobile is highly volatile but has strong potential in satellite broadband services according to Josh Arnold who initiated a strong buy rating. Equinor ASA's acquisition of Ørsted's stake and its strong cash flow make it an intriguing investment for Carlos Bonfiglio in the renewable energy sector.
Positive
Seeking Alpha
2 months ago
Cybin: Top Value Psychedelic Stock
Cybin is a promising value investment, with advanced clinical trials and strong institutional support, poised to disrupt mental health treatment. Cybin's proprietary drugs, CYB003 for depression and CYB004 for anxiety, show groundbreaking efficacy and shorter treatment time, enhancing patient and provider convenience. Cybin's trial results, robust IP portfolio, and solid financials de-risk its path to FDA approval, with a market cap significantly lower than competitors.
Charts implemented using Lightweight Charts™